Progress in the discovery of BACE inhibitors

Current Pharmaceutical Design

Volumn 11, Issue 26, 2005, Pages 3383-3404

  Thompson, Lorin A ^a   Bronson, Joanne J ^a   Zusi, F Christopher ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; HISPIDIN; HYDANTOIN; INDINAVIR; KMI 008; KMI 300; KMI 360; KMI 370; OM 00 3; OM 99 2; PHENYTOIN; PLANT EXTRACT; PROTEINASE INHIBITOR; STATINE DERIVATIVE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CHEMISTRY, PHARMACEUTICAL; ENDOPEPTIDASES; HUMANS; PROTEASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24944550164     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774370825     Document Type: Review

References (146)

1. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-38.
2. Plosker GL, Keating GM. Management of mild to moderate Alzheimer disease: defining the role of rivastigmine. Disease Management & Health Outcomes 2004; 12: 55-72.
3. Kornilova AY, Wolfe MS. Secretase inhibitors for Alzheimer's disease. Annu Rep Med Chem 2003; 38: 41-50.
4. Josien H. Recent advances in the development of g-secretase inhibitors. Curr Opin Drug Discov Devel 2002; 5: 513-25.
5. John V, Beck James P, Bienkowski Michael J, Sinha S, Heinrikson Robert L. Human beta-secretase (BACE) and BACE inhibitors. J Med Chem 2003; 46: 4625-30.
6. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci USA 2000; 97: 1456-60.
7. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase. Mol Cell Neurosci 1999; 14: 419-27.
8. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature (London) 1999; 402: 533-7.
9. Sinha S, Anderson JP; Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (London) 1999; 402: 537-40.
10. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (Washington, D. C.) 1999; 286: 735-41.
11. Yan R, Han P, Miao H, Greengard P, Xu H. The transmembrane domain of the Alzheimer's β-secretase (BACE1) determines its late Golgi localization and access to β-amyloid precursor protein (APP) substrate. J Biol Chem 2001; 276: 36788-96.
12. Huse JT, Pijak DS, Leslie GJ, Lee VMY, Doms RW. Maturation and endosomal targeting of β-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease β-secretase. J Biol Chem 2000; 275: 33729-37.
13. Citron M. β-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol Sci 2004; 25: 92-7.
14. Citron M. Emerging Alzheimer's disease therapies: inhibition of β-secretase. Neurobiol Aging 2002; 23: 1017-22.
15. Vassar R. BACE1. The β-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23: 105-13.
16. Vassar R. β-Secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 2002; 54: 1589-602.
17. Bennett BD, Babu-Khan S, Loeloff R, Louis J-C, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 2000; 275: 20647-51.
18. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic, protease family, maps to the Down critical region. FEBS Lett 2000; 468: 59-64.
19. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci USA 2000; 97: 9712-7.
20. Solans A, Estivill X, de la Luna S. A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein β-secretase. Cytogenet Cell Genet 2000; 89: 177-84.
21. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L Murdock PR, et al. ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site. Mol Cell Neurosci 2000; 16: 609-19.
22. Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, et al. BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003; 14: 81-8.
23. Piana S, Carloni P. Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: an ab initio study on the free enzyme. Proteins: Struct, Funct, Genet 2000; 39: 26-36.
24. Northrop DB. Follow the protons: A low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc Chem Res 2001; 34: 790-7.
25. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999; 402: 537-40.
26. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, et al. Design of substrate-based inhibitors of human beta-secretase. J Med Chem 2002; 45: 259-62.
27. John V, Tung J, Fang L, Mamo SS. Preparation of statine-derived tetrapeptides as inhibitors of β-secretase. PCT Int Appl 2000077030.
28. Hu B, Fan KY, Bridges K, Chopra R, Lovering F, Cole D, et al. Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors. Bioorg Med Chem Lett 2004; 14: 3457-60.
29. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, et al. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 2003; 46: 1799-802.
30. Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, et al. Design and synthesis of statine-Containing BACE inhibitors. Bioorg Med Chem Lett 2003; 13: 4335-9.
31. Pyring D, Lindberg J, Rosenquist A, Zuccarello G, Kvarnstroem I, Zhang H, et al. Design and Synthesis of Potent C2-Symmetric Diol-Based HIV-1 Protease Inhibitors: Effects of Fluoro Substitution. J Med Chem 2001; 44: 3083-91.
32. Kaldor SW, Dressman BA, Hammond M, Appelt K, Burgess J, Lubbehusen PP, et al. Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease. Bioorg Med Chem Lett 1995; 5: 721-6.
33. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, et al. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 2004; 47: 158-64.
34. Schostarez HJ, Chrusciel RA. Preparation of statine derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2003006021.
35. Kroemer RT, Ettmayer P, Hecht P. 3D-Quantitative Structure-Activity Relationships of Human Immunodeficiency Virus Type-1 Proteinase Inhibitors: Comparative Molecular Field Analysis of 2-Heterosubstituted Statine Derivatives-Implications for the Design of Novel Inhibitors. J Med Chem 1995; 38: 4917-28.
36. Scholz D, Billich A, Charpiot B, Ettmayer P, Lehr P, Rosenwirth B, et al. Inhibitors of HIV-1 Proteinase Containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral Activity. J Med Chem 1994; 37: 3079-89.
37. Shuto D, Kasai S, Kimura T Liu P, Hidaka K, Hamada T, et al. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003; 13: 4273-6.
38. Kimura T, Shuto D, Kasai S, Liu P, Hidaka K, Hamada T, et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004; 14: 1527-31.
39. Cozens RM, Bold G, Capraro HG, Faessler A, Mestan J, Lang M, et al. Synthesis and pharmacological evaluation of CGP 57813 and CGP 61755, HIV-1 protease inhibitors from the Phe-c-Phe peptidomimetic class. Antiviral Chemistry & Chemotherapy 1996; 7: 294-9.
40. Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, et al. Design of potent inhibitors for human brain memapsin 2 (β-secretase). J Am Chem Soc 2000; 122: 3522-3.
41. Tang JJN, Hong L, Ghosh, AK Inhibitors of memapsin 2 and use thereof. PCT Int Appl 2001000665.
42. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, et al. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (Washington, D. C.) 2000; 290: 150-3.
43. Turner RT III, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, et al. Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design [Erratum for Volume 40, Number 34, August 28, 2001, pages 10001-10]. Biochemistry 2001; 40: 12230.
44. Turner RT 3rd, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 2001; 40: 10001-6.
45. Hong L, Turner RT 3rd, Koelsch G, Shin D, Ghosh Arun K, Tang J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 2002; 41: 10963-7.
46. Lamar J, Hu J, Bueno AB, Yang H-C, Guo D, Copp JD, et al. Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg Med Chem Lett 2004; 14: 239-43.
47. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 2002; 277: 4687-93.
48. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 2001; 44: 2865-8.
49. Tang JJN, Koelsch G, Ghosh AK Inhibitors of memapsin 2 and their use in Alzheimer's disease treatment. PCT Int Appl 2002053594.
50. Ghosh AK, Tang J, Bilcer G, Chang W, Hong L, Koetsch G, et al. Design of β-secretase inhibitors for treatment of Alzheimer's disease based on crystal structures of β-secretase and side chain interactions in inhibitor complexes. PCT Int Appl 2003039454.
51. Boyd JG, Singleton DH An inhibitor of beta amyloid cleavage enzyme. Eur Pat Appl 1233021.
52. Chen S-H, Lamar J, Guo D, Kohn T, Yang H-C, McGee J, et al. P3 cap modified Phe*-Ala series BACE inhibitors. Bioorg Med Chem Lett 2004; 14: 245-50.
53. Brady SF, Singh S, Crouthamel M-C, Holloway MK, Coburn CA, Garsky VM, et al. Rational design and synthesis of selective BACE-1 inhibitors. Bioorg Med Chem Lett 2004; 14: 601-4.
54. Lai M-T, Crouthamel MC, Brady SF. Synthesis of β-secretase inhibitors for treating Alzheimer's disease. PCT Int Appl 2003099202.
55. Yang W, Cary DR, Jacobs JW, Lu W, Lu Y, Sun J, et al. Preparation of amino carboxamide derivatives as aspartyl protease inhibitors. PCT Int Appl 2003106405.
56. Faller A, Milner PH, Ward JG. Hydroxyethylene compounds with Asp-2 inhibitory activity. PCT Int Appl 2003045903.
57. Hom R, Mamo S, Tung J, Gailunas A, John V, Fang L. Preparation of hydroxyethylenes with peptide subunits for pharmaceutical use in the treatment of Alzheimer's disease. PCT Int Appl 2001070672.
58. Hom R, Mamo S, Tung J, Gailunas A, John V, Fang L. Preparation of 5-amino-4-hydroxypentanoic acid derivatives for treating Alzheimer's disease. U.S. Pat Appl Publ 2003013881.
59. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, et al. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994; 91: 4096-100.
60. Hom R. Preparation of allylamides useful in the treatment of Alzheimer's disease. PCT Int Appl 2003030886.
61. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995; 117: 1181-2.
62. Dohnalek J, Hasek J, Duskova J, Petrokova H, Hradilek M, Soucek M, et al. Hydroxyethylamin Isostere of an HIV-1 Protease Inhibitor Prefers Its Amine to the Hydroxy Group in Binding to Catalytic Aspartates. A Synchrotron Study of HIV-1 Protease in Complex with a Peptidomimetic Inhibitor. J Med Chem 2002; 45: 1432-8.
63. Tamamura H, Kato T, Otaka A, Fujii N. Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org Biomol Chem 2003; 1: 2468-73.
64. Press Release, Elan Corp. plc, August 10, 2000.
65. Maillaird M, Hom C, Gailunas A, Jagodzinska B, Fang LY, John V, et al. Preparation of substituted amines to treat Alzheimer's disease. PCT Int Appl 2002002512.
66. Fang LY, Hom R, John V, Maillaird M. Preparation of substituted amines for treating Alzheimer's disease. PCT Int Appl 2002002505.
67. Fang LY. John V. Compounds to treat Alzheimer's disease. PCT Int Appl 2002002506.
68. Beck JP, Gailunas A, Hom R, Jagodzinska B, John V, Maillaird M. Preparation of disubstituted amines for treating Alzheimer's disease. PCT Int Appl 2002002520.
69. Beck JP, Gailunas A, Hom R, Jagodzinska B, John V, Maillaird M. Preparation of disubstituted amines for treating Alzheimer's disease. PCT Int Appl 2002002518.
70. Becker S. Atazanavir: improving the HIV protcase inhibitor class. Expert Review of Anti-Infective Therapy 2003; 1: 403-13.
71. Varghese J, Jagodzinska B, Maillard M, Beck JP, Tenbrink RE, Getman D. Preparation of substituted amines prodrugs useful in treating Alzheimer's disease. PCT Int Appl 2003072535.
72. Fobian YM, Freskos JN, Jagodzinska BA. Preparation of 1, 3-diamino-2-hydroxypropane derivatives as beta-secretase enzyme inhibitors. PCT Int Appl 2004022523.
73. Hurley TR, Colson CE, Hicks G, Ryan MJ. Orally active water-soluble N, O-acyl transfer products of a β, γ-bishydroxyl amide containing renin inhibitor. J Med Chem 1993; 36: 1496-8.
74. Kiso Y, Matsumoto H, Yamaguchi S, Kimura T. Design of small peptidomimetic HIV-1 protease inhibitors and prodrug forms. Lett Pep Sci 1999; 6: 275-81.
75. Hamada Y, Ohtake J, Sohma Y, Kimura T, Hayashi Y, Kiso Y. New water-soluble prodrugs of HIV protease inhibitors based on O -> N intramolecular acyl migration. Bioorg Med Chem 2002; 10: 4155-67.
76. Hamada Y, Matsumoto H, Yamaguchi S, Kimura T, Hayashi Y, Kiso Y. Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O-> N intramolecular acyl migration: Design, synthesis and kinetic study. Bioorg Med Chem 2004; 12: 159-70.
77. Uchikawa O, Aso K, Koike T, Tarui N, Hirai K. Substituted amino compounds and use thereof. PCT Int Appl 2004014843.
78. Schostarez H, Chrusciel RA. Preparation of peptide-related hydrazine derivatives for treating Alzheimer's disease. PCT Int Appl 2002100410.
79. Schostarez H, Chrusciel RA, Centko RS. Acylaminopropyl-hydrazines as β-secretase inhibitors. PCT Int Appl 2002094768.
80. Gailunas A, Hom R, John V, Maillard M, Chrusciel RA, Fisher J, et al. Preparation of N-(3-amino-2-hydroxy-propyl) substituted alkanamides as inhibitors of the beta secretase enzyme for treating Alzheimer's disease. PCT Int Appl 2003006421
81. John V, Maillard M, Jagodzinska B, Beck JP, Gailunas A, Fang L, et al. Preparation of N, N′-substituted-1, 3-diamino-2-hydroxy-propanes for treating Alzheimer's disease. PCT Int Appl 2003040096.
82. Decicco CP, Tebben AJ, Thompson LA, Combs AP. Preparation of novel α-amino-γ-lactams as β-secretase inhibitors. PCT Int Appl 2004013098.
83. Horwell DC, Howson W, Rees DC. 'Peptoid' design. Drug Des Discov 1994; 12: 63-75.
84. Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, Banville S, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci USA 1992; 89: 9367-71.
85. Hom R, Varghese J. Preparation of hydroxyaminopropyl-benzamides for the treatment of Alzheimer's disease. PCT Int Appl 2004029019.
86. Wolfe MS, Selkoe DJ. Preparation of (hydroxyethyl)ureas as inhibitors of Alzheimer's β-amyloid production. PCT Int Appl 2002014264.
87. Thaisrivongs S, Pals DT, Kroll LT, Turner SR, Han FS. Renin inhibitors. Design of angiotensinogen transition-state analogs containing novel (2R, 3R, 4R, 5S)-5-amino-3, 4-dihydroxy-2-isopropyl-7-methyloctanoic acid. J Med Chem 1987; 30: 976-82.
88. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA 1990; 87: 7472-6.
89. Thaisrivongs S, Tomasselli AG, Moon JB, Hui J, McQuade TJ, Turner SR, et al. Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. J Med Chem 1991; 34: 2344-56.
90. Schostarez HJ, Chrusciel RA. Preparation of amine diols as β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2003006453.
91. Romero AG, Schostarez H, Roels CM. Preparation of amine 1, 2- and 1, 3-diol alditols and their use for treatment of Alzheimer's disease. PCT Int Appl 2003043975.
92. Schostarez HJ, Chrusciel RA. Preparation of aminediols as β-secretase inhibitors for the treatment of Alzheimer's and other diseases characterized by deposition of Ab peptide. PCT Int Appl 2002100818.
93. Beck JP. Preparation of hydroxy substituted indanylamides for the treatment of Alzheimer's disease. PCT Int Appl 2003037325.
94. Schostarez HJ. Preparation of quinaldoyl amine derivatives of oxo- and hydroxy-substituted hydrocarbons for treating Alzheimer's disease. PCT Int Appl 2003020370.
95. Beck JT. Substituted peptides useful in the treatment of Alzheimer's disease, and. Preparation thereof. PCT Int Appl 2004037179.
96. John V. Methods for treating Alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere. PCT Int Appl 2004002478.
97. Tucker JA, Sherer BA, Xu YZ, Brogley L, Pulley SR, Jacobs JS, et al. Hydroxypropyl amides for the treatment of Alzheimer's disease. U.S. Pat Appl Publ 20040039034.
98. Fisher JF, Jacobs JS, Scherer BA. Preparation of arylhydroxypropylamines used for treatment of Alzheimer's disease and to reduce amyloid beta peptide formation. PCT Int Appl 2003029169.
99. Schostarez HJ, Chrusciel RA. Preparation of diamine diols as β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2003006013.
100. Jagodzinska B, Warpehoski MA. Preparation of substituted amino carboxamides for the treatment of Alzheimer's disease. PCT Int Appl 2003057721.
101. John V. Preparation of peptide isosteres containing a heterocycle useful in the treatment of Alzheimer's disease. PCT Int Appl 2003047576.
102. John V, Hom R, Tucker J. Preparation of β-hydroxyamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2003002122.
103. Gailunas A, Tucker JA, John V. Preparation of phenethylamines for the treatment of Alzheimer's disease. PCT Int Appl 2003027068.
104. Beck JP, Drowns M, Warpehoski MA. Preparation of ring-containing aminoether carboxamides as β-secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of Ab-peptide. PCT Int Appl 2004024675.
105. Maillard M, Baldwin ET, Beck JT, Hughes R, John V, Pulley SR, et al. Preparation of ring-containing N-acetyl 2-hydroxy-1, 3-diaminoalkanes as β-secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of Ab-peptide. PCT Int Appl 2004024081.
106. Szewczuk Z, Rebholz KL, Rich DH. Synthesis and biological activity of new conformationally restricted analogs of pepstatin. Int J Pept Protein Res 1992; 40: 233-42.
107. Brotherton-Pleiss CE, Newman SR, Waterbury LD, Schwartzberg MS. Design and synthesis of conformationally restricted renin inhibitors. Pept Chem Biol, Proc Am Pept Symp 12th 1992; 816-17.
108. Podlogar BL, Farr RA, Friedrich D, Tarnus C, Huber EW, Cregge RJ, et al. Design, Synthesis, and Conformational Analysis of a Novel Macrocyclic HIV-Protease Inhibitor. J Med Chem 1994; 37: 3684-92.
109. Smith RA, Coles PJ, Chen JJ, Robinson VJ, MacDonald ID, Carriere J, et al. Design, synthesis, and activity of conformationally-constrained macrocyclic peptide-based inhibitors of HIV protease. Bioorg Med Chem Lett 1994; 4: 2217-22.
110. Chen JJ, Coles PJ, Arnold LD, Smith RA, MacDonald ID, Carriere J, et al. Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease. Bioorg Med Chem Lett 1996; 6: 435-8.
111. Abbenante G, Bergman DA, Brinkworth RI, March DR, Reid RC, Hunt PA, et al. Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease. Bioorg Med Chem Lett 1996, 6: 2531-6.
112. Pulley SR, Beck JP, Tenbrink RE. Macrocycles useful in the treatment of alzheimer's disease. PCT Int Appl 2002100856.
113. Pulley SR, Beck JP, Tenbrink RE, Jacobs JS. Preparation of macrocycles useful in the treatment of Alzheimer's disease. PCT Int Appl 2002100399.
114. Luly JR, Bolis G, BaMaung N, Soderquist J, Dellaria JF, Stein H, et al. New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site. J Med Chem 1988; 31: 532-9.
115. Plummer M, Hamby JM, Hingorani G, Batley BL, Rapundalo ST. Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(->P3)-P1 sites. Bioorg Med Chem Lett 1993; 3: 2119-24.
116. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7: 493-504.
117. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
118. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: e1-e8.
119. Wood JM, Maibaum J, Rahuel J, Gruetter MG, Cohen N-C, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
120. John V, Maillard M. Methods of treating Alzheimer's disease using and method of preparing d-amino-γ-hydroxy-ω-arylalkanoic acid amides. PCT Int Appl 2003103653.
121. Maillard M, Varghese J. Methods of treating Alzheimers disease using aromatically substituted ω-amino-alkanoic acid amides and alkanoic acid diamides. PCT Int Appl 2003103652.
122. Tenbrink R, Maillard M, Warpehoski M. Preparation of substituted hydroxyethylamines as β-secretase inhibitors. PCT Int Appl 2003050073.
123. Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, D'Arcy A, et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chemistry & Biology 1999; 6: 127-31.
124. Marki HP, Binggeli A, Bittner B, Bohner-Lang V, Breu V, Bur D, et al. Piperidine renin inhibitors: from leads to drug candidates. Farmaco 2001; 56: 21-7.
125. Vieira E, Binggeli A, Breu V, Bur D, Fischli W, Guller R, et al. Substituted piperidines - highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg Med Chem Lett 1999; 9: 1397-402.
126. Guller R, Binggeli A, Breu V, Bur D, Fischli W, Hirth G, et al. Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg Med Chem Lett 1999; 9: 1403-8.
127. Bursavich MG, West CW, Rich DH. From Peptides to Non-Peptide Peptidomimetics: Design and Synthesis of New Piperidine Inhibitors of Aspartic Peptidases. Org Lett 2001; 3: 2317-20.
128. Bhisetti GR, Saunders JO, Murcko MA, Lepre CA, Britt SD, Come JH, et al. Preparation of β-carbolines and other inhibitors of BACE-1 aspartic proteinase useful against Alzheimer's and other BACE-mediated diseases. PCT Int Appl 2002088101.
129. Nieman JA, Fang L, Jagodzinska B. Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes. PCT Int Appl 2002076440.
130. John V, Moon JB, Pulley SR, Rich DH, Brown DL, Jagodzinska B, et al. Preparation of substituted piperidines and piperazines useful as β-secretase inhibitors against Alzheimer's disease. PCT Int Appl 2003043987.
131. Boss C, Bur D, Fischli W, Jenck F, Weller T. Preparation of substituted 3- and 4-(aminomethyl)piperidines for use as β-secretase inhibitors in the treatment of Alzheimer's disease. PCT Int Appl 2004002483.
132. Boss C, Bur D, Fischli W, Jenck F, Weller T. Preparation of piperidines for the treatment of central nervous system disorders. PCT Int Appl 2004009549.
133. Willems H. Preparation of piperazines as β-amyloid converting enzyme (BACE) inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2004020422.
134. Park I-H, Jeon S-Y, Lee H-J, Kim S-I, Song K-S. A beta-Secretase (BACE1) Inhibitor Hispidin from the Mycelial Cultures of Phellinus linteus. Planta Med 2004; 70: 143-6.
135. Jeon S-Y, Bae K, Seong Y-H, Song K-S. Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 2003; 13: 3905-8.
136. Beck JP. Preparation and use of aza-bicyclononanes for the treatment of Alzheimer's disease. PCT Int Appl 2003000261.
137. Dietrich A, Nimz O, Rester U, Fecke W, Haemmerle M, Baier F. β-secretase inhibitors for use in treatment of diseases caused by deposits of β-amyloid peptides. PCT Int Appl 2003059346.
138. Willems H, Harris WH. Preparation of N-sulfonyl amino acid derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2004020402.
139. Willems H, Gordon R. Protected amino acid derivatives for the treatment of Alzheimer's disease. Brit UK Pat Appl 2392443.
140. Willems H, Porter B. Preparation of hydroxysuccinamide compounds for the treatment of Alzheimer's disease. Brit UK Pat Appl 2391547.
141. Tung JS, Guinn AC, Thorsett G, Pleiss MA. Preparation of hydroxyalkanoyl aminopyrazoles and related compounds for inhibiting β-amyloid peptide release. PCT Int Appl 2003064396.
142. Miyamoto M, Matsui J, Fukumoto H, Tarui N. Preparation of 2-[2-amino- or 2-(N-heterocyclyl)ethyl]-6-(4-biphenylylmethoxy) tetralin derivatives as β-secretase inhibitors. PCT Int Appl 2001087293.
143. Qiao L, Etcheberrigaray R. Preparation of phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs as β-secretase inhibitors useful in the treatment of Alzheimer's disease. PCT Int Appl 2002096897.
144. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 2003; 9(6): 427-47.
145. Hersh LB. Peptidases, proteases and amyloid beta-peptide catabolism. Curr Pharm Design 2003; 9(6): 449-54.
146. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Design 2004; 10(13): 1469-92.